Pfizer has announced that the Scottish Medicines Consortium (SMC) has accepted Ibrance (palbociclib) for use within NHS Scotland for the treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy in the advanced breast cancer setting.
The approval means that palbociclib can be used in combination with the hormone treatment fulvestrant to treat women with HR+, HER2- advanced breast cancer who have already had earlier rounds of hormone therapy in the advanced setting. It is estimated that approximately 400 women in Scotland each year could now benefit from this decision.
The SMC decision was based on data from the phase III clinical trial, PALOMA-3, which evaluated palbociclib in combination with fulvestrant compared to placebo plus fulvestrant in women with HR+, HER2- metastatic breast cancer whose disease had progressed on or after prior endocrine therapy.
The National Institute for Health and Care Excellence (NICE) appraisal for palbociclib in combination with fulvestrant is currently underway and a decision is expected before the end of the year.
Dr Olivia Ashman, Oncology Medical Director, Pfizer UK, said: “We are delighted with today’s news from the SMC. Treating women with palbociclib and fulvestrant has been found to be an important and effective option for those who have already received earlier rounds of hormone therapy and we are pleased that this combination of medicines will now be routinely available in Scotland.
“We know that this approval from the SMC will be meaningful for the many patients and families who are affected by this type of advanced breast cancer and we hope the same outcome will be reached by NICE later this year.”